Common Antibiotics

Total Page:16

File Type:pdf, Size:1020Kb

Common Antibiotics COMMON ANTIBIOTICS DANA BARTLETT, RN, BSN, MSN, MA Dana Bartlett is a professional nurse and author. His clinical experience includes 16 years of ICU and ER experience and over 20 years of as a poison control center information specialist. Dana has published numerous CE and journal articles, written NCLEX material, written textbook chapters, and done editing and reviewing for publishers such as Elsevire, Lippincott, and Thieme. He has written widely on the subject of toxicology and was recently named a contributing editor, toxicology section, for Critical Care Nurse journal. He is currently employed at the Connecticut Poison Control Center and is actively involved in lecturing and mentoring nurses, emergency medical residents and pharmacy students. ABSTRACT There are many antibiotics available in the United States to treat various forms of infection. Understanding the benefits and risks of antibiotic therapy, such as adverse effects associated with specific antibiotics, and the safe administration and monitoring of patients receiving antibiotics can appear daunting. However, issues of antibiotic therapy may be approached by knowing the adverse effects common to all antibiotics, those at risk of having adverse effects and the level of severity of adverse effects as well as any testing required for detection. The main classes of antibiotics and the specific antibiotics available in the U.S., in particular, the aminoglycoside, carbapenem, cephalosporin, glycopeptide, lincosamide, macrolide, penicillin, quinolone, sulfonamide, tetracycline, metronidazole and nitrofurantoin antibiotics are discussed. nursece4less.com nursece4less.com nursece4less.com nursece4less.com nursece4less.com nursece4less.com 1 Continuing Nursing Education Course Planners William A. Cook, PhD, Director, Douglas Lawrence, MA, Webmaster, Susan DePasquale, CGRN, MSN, FPMHNP-BC, Lead Nurse Planner Policy Statement This activity has been planned and implemented in accordance with the policies of NurseCe4Less.com and the continuing nursing education requirements of the American Nurses Credentialing Center's Commission on Accreditation for registered nurses. It is the policy of NurseCe4Less.com to ensure objectivity, transparency, and best practice in clinical education for all continuing nursing education (CNE) activities. Continuing Education Credit Designation This educational activity is credited for 3 hours. Nurses may only claim credit commensurate with the credit awarded for completion of this course activity. Pharmacology content is credited for 3 hours. Statement of Learning Need Properties of antibiotics influence medical guidelines for the treatment of an infectious process and follow up care in terms of antibiotic use and monitoring of treatment outcomes. The rise of antibiotic resistance poses a significant health risk, which health professionals must consider when deciding treatment in terms of antibiotic type and drug qualities. nursece4less.com nursece4less.com nursece4less.com nursece4less.com nursece4less.com nursece4less.com 2 Course Purpose To provide nurses with knowledge of common antibiotics, as well as the indications and the correct and safe administration of antibiotics. Target Audience Advanced Practice Registered Nurses and Registered Nurses (Interdisciplinary Health Team Members, including Vocational Nurses and Medical Assistants may obtain a Certificate of Completion) Course Author & Planning Team Conflict of Interest Disclosures Dana Bartlett, RN, BSN, MSN, MA, William S. Cook, PhD, Douglas Lawrence, MA, Susan DePasquale, CGRN, MSN, FPMHNP-BC – all have no disclosures Acknowledgement of Commercial Support There is no commercial support for this course. Activity Review Information Reviewed by Susan DePasquale, CGRN, MSN, FPMHNP-BC Release Date: 12/12/2015 Termination Date: 12/12/2018 Please take time to complete a self-assessment of knowledge, on page 4, sample questions before reading the article. Opportunity to complete a self-assessment of knowledge learned will be provided at the end of the course. nursece4less.com nursece4less.com nursece4less.com nursece4less.com nursece4less.com nursece4less.com 3 1. Antibiotic-associated diarrhea a. can have a delayed onset and cause serious complications. b. occurs after the first dose and is always mild and self-limiting. c. only occurs in women >age 60. d. typically affects hospitalized neonates. 2. Allergic reactions to antibiotics a. always happen within one hour after a dose. b. can be delayed in onset. c. are always severe and life-threatening. d. only occur in people who have a compromised immune system. 3. True or false: Someone who is allergic to penicillin may be allergic to cephalosporins. a. True b. False. 4. Patients who are receiving antibiotic therapy should be monitored for a. osteoporosis. b. polycythemia. c. diabetes mellitus. d. nephrotoxicity. 5. Which of these antibiotics is well known for causing ototoxicity? a. Carbapenems. b. Metronidazole. c. Aminoglycosides. d. Quinilones. nursece4less.com nursece4less.com nursece4less.com nursece4less.com nursece4less.com nursece4less.com 4 Introduction This learning module discusses antibiotic therapy as well as specific antibiotics. In particular, the aminoglycoside, carbapenem, cephalosporin, glycopeptide, lincosamide, macrolide, penicillin, quinolone, sulfonamide, and tetracycline antibiotics, and metronidazole and nitrofurantoin are covered in the following sections. Antibiotics that are not available in the United States will not be covered. Specific aspects of antibiotic therapy raised in the following sections include: 1. Mechanism of action 2. Considerations for administration 3. Adverse effects/warnings including the U.S. boxed warning, more common, i.e., >10% reporting rate, adverse effects of specific antibiotics, and, adverse effects or warnings that are reported for all of the antibiotics of a particular class (frequency of an adverse reaction not reported in commonly used drug reference sources is not discussed) 4. Labeled uses In addition, issues that are important for the safe administration of antibiotics will be covered in this course: adverse effects common to all antibiotics, allergic reactions and cross-reactivity, and antibiotic resistance. nursece4less.com nursece4less.com nursece4less.com nursece4less.com nursece4less.com nursece4less.com 5 Learning Break: The term antibiotic is defined as a drug that is used to treat an infection, but it is commonly used to refer to drugs that are used to treat bacterial infections. This is technically incorrect but, given the widespread and commonly accepted use of the term antibiotic in that context, its common use will be retained in this module. Discussion of drug dosages, interactions, off-label uses, and all of the possible adverse effects of each antibiotic and/or class of antibiotics would not be practical here, and that information can easily be found in drug reference books and package inserts. Information that is particular to each of the antibiotic classes and important for safe administration will be the primary focus. The primary source of information is Lexi-Comp® or Lexi-Drugs® unless citations shown in the following sections specifically indicate otherwise. A Boxed Warning, sometimes called a black box warning, is a warning that is required by the Food and Drug Administration (FDA) to be included and prominently featured in the prescribing information of a drug if there is potential for a severe adverse reaction (death, permanent disability, a life-threatening event) in proportion to the potential benefit of the drug, which requires cautious assessment of the drug’s risks and benefits; or if there is a serious adverse reaction that can be prevented or reduced in severity by appropriate use of the drug, i.e., patient selection, careful monitoring, avoiding certain concomitant therapy. nursece4less.com nursece4less.com nursece4less.com nursece4less.com nursece4less.com nursece4less.com 6 Mechanism Of Antibiotic Action Antibiotics are used to treat infections caused by susceptible bacteria and all of the antibiotics interfere with some aspect of the biochemical processes that are necessary for these microorganisms to survive. The mechanisms of action of antibiotics are quite complex and are specific to each class of antibiotic but the essential action of most antibiotics is disruption of the bacteria cell membrane, most often by inhibiting protein synthesis and making it impossible for the bacteria to maintain intracellular homeostasis. Antibiotics are not effective treatment for fungal or viral infections. Adverse Effects Reference books and package inserts provide extensive lists of adverse effects associated with and/or caused by a drug, but these information sources seldom quantify how likely it is that a specific adverse effect will occur or which patients are at risk. Clinicians want to know what adverse effects are of a practical concern and what to do about them, but the drug information references do not often provide this type of guidance. For example, package inserts for antibiotics warn that these drugs can cause kidney and liver damage and should be used with caution if the patient has, or is at risk for, hepatic and/or renal impairment. The clinician wants to know how frequently and to whom these adverse effects will occur but very often this information is not given. A more specific example is that a commonly used drug information source lists 37 adverse effects associated with cephalexin; these range in severity from nausea to anaphylaxis
Recommended publications
  • Criteria for Use of Dalbavancin for Acute Bacterial Skin/Soft Tissue Infection (Abssti)
    Criteria for Use of Dalbavancin for Acute Bacterial Skin/Soft Tissue Infection (abSSTI) 1. Patients meeting any of the following are NOT ELIGIBLE for dalbavancin therapy: a. History of hypersensitivity reaction to lipoglycopeptide antibiotics (vancomycin, televancin, dalbavancin, oritavancin). b. Patients with acute bacterial skin or skin structure infections such as superficial/simple cellulitis/erysipelas, impetiginous lesion, furuncle, or simple abscess that only requires surgical drainage for cure. c. Infection thought to be caused by gram-negative bacteria d. Infection due to an organism suspected or known to be resistant to dalbavancin or vancomycin 2. For outpatient use (i.e. ED) a. Contact infectious disease for authorization: ABX approval pager (see ON-CALL schedule) b. The following clinical criteria must be met: i. Pre-antibiotic blood cultures must be drawn. ii. Clinical condition expected to require ≥ 24 hours of IV antibiotics – must not qualify for oral antibiotic therapy. iii. Presence of cellulitis, major abscess or a wound infection associated with at least 75cm2 of erythema highly suspected or known to be caused by gram-positive bacteria. iv. The size of the infection must be clearly documented and/or outlined prior to leaving the ED, preferably with a photograph. v. Patient to be discharged to home ± home health (not to skilled nursing facility). c. Required follow up must be set up prior to leaving the ED: i. Must document patient contact info for follow up, preferably reliable cell phone number. ii. Must have follow up within 48-72H with Dr. Turnipseed (916-765-0196) or Rominski. 1. Email patient name, MRN, and phone number.
    [Show full text]
  • Antibiotic Assay Medium No. 3 (Assay Broth) Is Used for Microbiological Assay of Antibiotics. M042
    HiMedia Laboratories Technical Data Antibiotic Assay Medium No. 3 (Assay Broth) is used for M042 microbiological assay of antibiotics. Antibiotic Assay Medium No. 3 (Assay Broth) is used for microbiological assay of antibiotics. Composition** Ingredients Gms / Litre Peptic digest of animal tissue (Peptone) 5.000 Beef extract 1.500 Yeast extract 1.500 Dextrose 1.000 Sodium chloride 3.500 Dipotassium phosphate 3.680 Potassium dihydrogen phosphate 1.320 Final pH ( at 25°C) 7.0±0.2 **Formula adjusted, standardized to suit performance parameters Directions Suspend 17.5 grams in 1000 ml distilled water. Heat if necessary to dissolve the medium completely. Sterilize by autoclaving at 15 lbs pressure (121°C) for 15 minutes. Advice:Recommended for the Microbiological assay of Amikacin, Bacitracin, Capreomycin, Chlortetracycline,Chloramphenicol,Cycloserine,Demeclocycline,Dihydrostreptomycin, Doxycycline, Gentamicin, Gramicidin, Kanamycin, Methacycline, Neomycin, Novobiocin, Oxytetracycline, Rolitetracycline, Streptomycin, Tetracycline, Tobramycin, Trolendomycin and Tylosin according to official methods . Principle And Interpretation Antibiotic Assay Medium is used in the performance of antibiotic assays. Grove and Randall have elucidated those antibiotic assays and media in their comprehensive treatise on antibiotic assays (1). Antibiotic Assay Medium No. 3 (Assay Broth) is used in the microbiological assay of different antibiotics in pharmaceutical and food products by the turbidimetric method. Ripperre et al reported that turbidimetric methods for determining the potency of antibiotics are inherently more accurate and more precise than agar diffusion procedures (2). Turbidimetric antibiotic assay is based on the change or inhibition of growth of a test microorganims in a liquid medium containing a uniform concentration of an antibiotic. After incubation of the test organism in the working dilutions of the antibiotics, the amount of growth is determined by measuring the light transmittance using spectrophotometer.
    [Show full text]
  • Antibacterial Residue Excretion Via Urine As an Indicator for Therapeutical Treatment Choice and Farm Waste Treatment
    antibiotics Article Antibacterial Residue Excretion via Urine as an Indicator for Therapeutical Treatment Choice and Farm Waste Treatment María Jesús Serrano 1, Diego García-Gonzalo 1 , Eunate Abilleira 2, Janire Elorduy 2, Olga Mitjana 1 , María Victoria Falceto 1, Alicia Laborda 1, Cristina Bonastre 1 , Luis Mata 3 , Santiago Condón 1 and Rafael Pagán 1,* 1 Instituto Agroalimentario de Aragón-IA2, Universidad de Zaragoza-CITA, 50013 Zaragoza, Spain; [email protected] (M.J.S.); [email protected] (D.G.-G.); [email protected] (O.M.); [email protected] (M.V.F.); [email protected] (A.L.); [email protected] (C.B.); [email protected] (S.C.) 2 Public Health Laboratory, Office of Public Health and Addictions, Ministry of Health of the Basque Government, 48160 Derio, Spain; [email protected] (E.A.); [email protected] (J.E.) 3 Department of R&D, ZEULAB S.L., 50197 Zaragoza, Spain; [email protected] * Correspondence: [email protected]; Tel.: +34-9-7676-2675 Abstract: Many of the infectious diseases that affect livestock have bacteria as etiological agents. Thus, therapy is based on antimicrobials that leave the animal’s tissues mainly via urine, reaching the environment through slurry and waste water. Once there, antimicrobial residues may lead to antibacterial resistance as well as toxicity for plants, animals, or humans. Hence, the objective was to describe the rate of antimicrobial excretion in urine in order to select the most appropriate molecule while reducing harmful effects. Thus, 62 pigs were treated with sulfamethoxypyridazine, Citation: Serrano, M.J.; oxytetracycline, and enrofloxacin. Urine was collected through the withdrawal period and analysed García-Gonzalo, D.; Abilleira, E.; via LC-MS/MS.
    [Show full text]
  • Demeclocycline
    PATIENT & CAREGIVER EDUCATION Demeclocycline This information from Lexicomp® explains what you need to know about this medication, including what it’s used for, how to take it, its side effects, and when to call your healthcare provider. What is this drug used for? It is used to treat bacterial infections. It may be given to you for other reasons. Talk with the doctor. What do I need to tell my doctor BEFORE I take this drug? If you have an allergy to demeclocycline or any other part of this drug. If you are allergic to this drug; any part of this drug; or any other drugs, foods, or substances. Tell your doctor about the allergy and what signs you had. If you are taking penicillin. If you are breast-feeding or plan to breast-feed. This is not a list of all drugs or health problems that interact with this drug. Tell your doctor and pharmacist about all of your drugs Demeclocycline 1/8 (prescription or OTC, natural products, vitamins) and health problems. You must check to make sure that it is safe for you to take this drug with all of your drugs and health problems. Do not start, stop, or change the dose of any drug without checking with your doctor. What are some things I need to know or do while I take this drug? Tell all of your health care providers that you take this drug. This includes your doctors, nurses, pharmacists, and dentists. Avoid driving and doing other tasks or actions that call for you to be alert until you see how this drug affects you.
    [Show full text]
  • TETRACYCLINES and CHLORAMPHENICOL Protein Synthesis
    ANTIMICROBIALS INHIBITING PROTEIN SYNTHESIS AMINOGLYCOSIDES MACROLIDES TETRACYCLINES AND CHLORAMPHENICOL Protein synthesis Aminoglycosides 1. Aminoglycosides are group of natural and semi -synthetic antibiotics. They have polybasic amino groups linked glycosidically to two or more aminosugar like: sterptidine, 2-deoxy streptamine, glucosamine 2. Aminoglycosides which are derived from: Streptomyces genus are named with the suffix –mycin. While those which are derived from Micromonospora are named with the suffix –micin. Classification of Aminoglycosides 1. Systemic aminogycosides Streptomycin (Streptomyces griseus) Gentamicin (Micromonospora purpurea) Kanamycin (S. kanamyceticus) Tobramycin (S. tenebrarius) Amikacin (Semisynthetic derivative of Kanamycin) Sisomicin (Micromonospora inyoensis) Netilmicin (Semisynthetic derivative of Sisomicin) 2. Topical aminoglycosides Neomycin (S. fradiae) Framycetin (S. lavendulae) Pharmacology of Streptomycin NH H2N NH HO OH Streptidine OH NH H2N O O NH CHO L-Streptose CH3 OH O HO O HO NHCH3 N-Methyl-L- Glucosamine OH Streptomycin Biological Source It is a oldest aminoglycoside antibiotic obtained from Streptomyces griseus. Antibacterial spectrum 1. It is mostly active against gram negative bacteria like H. ducreyi, Brucella, Yersinia pestis, Francisella tularensis, Nocardia,etc. 2. It is also used against M.tuberculosis 3. Few strains of E.coli, V. cholerae, H. influenzae , Enterococci etc. are sensitive at higher concentration. Mechanism of action Aminoglycosides bind to the 16S rRNA of the 30S subunit and inhibit protein synthesis. 1. Transport of aminoglycoside through cell wall and cytoplasmic membrane. a) Diffuse across cell wall of gram negative bacteria by porin channels. b) Transport across cell membrane by carrier mediated process liked with electron transport chain 2. Binding to ribosome resulting in inhibition of protein synthesis A.
    [Show full text]
  • Evaluation of Pharmacodynamic Interactions Between Telavancin
    Infect Dis Ther DOI 10.1007/s40121-016-0121-2 ORIGINAL RESEARCH Evaluation of Pharmacodynamic Interactions Between Telavancin and Aztreonam or Piperacillin/ Tazobactam Against Pseudomonas aeruginosa, Escherichia coli and Methicillin-Resistant Staphylococcus aureus Juwon Yim . Jordan R. Smith . Katie E. Barber . Jessica A. Hallesy . Michael J. Rybak Received: May 2, 2016 Ó The Author(s) 2016. This article is published with open access at Springerlink.com ABSTRACT Methods: In vitro one-compartment PK/PD models were run over 96 h simulating TLV Introduction: In clinical trials comparing 10 mg/kg every 48 h, ATM 500 mg every 8 h telavancin (TLV) with vancomycin for and PTZ continuous infusion 13.5 g over 24 h treatment of hospital-acquired pneumonia, alone and in combination against P. aeruginosa, TLV demonstrated lower clinical cure rates E. coli and methicillin-resistant S. aureus than vancomycin in patients who had mixed (MRSA). The efficacy of antimicrobials was gram-positive and -negative infections and were evaluated by plotting time-kill curves and concomitantly treated with either aztreonam calculating the reduction in log10 cfu/ml over (ATM) or piperacillin/tazobactam (PTZ). Here, 96 h. we investigated therapeutic interactions Results: Against both MRSA strains, TLV was between TLV and ATM or PTZ in an in vitro rapidly bactericidal at 4 h and maintained its pharmacokinetic/pharmacodynamic (PK/PD) activity over 96 h with no observed antagonism model under simulated reduced renal function by either ATM or PTZ. PTZ maintained conditions. bacteriostatic and bactericidal activities against Enhanced content To view enhanced content for this E. coli ATCC 25922 and clinical strain R1022 at article go to http://www.medengine.com/Redeem/ 96 h, whereas both strains regrew as soon as 22E4F0603737CC9F.
    [Show full text]
  • Demeclocycline in the Treatment of the Syndrome of Inappropriate Secretion of Antidiuretic Hormone
    Thorax: first published as 10.1136/thx.34.3.324 on 1 June 1979. Downloaded from Thorax, 1979, 34, 324-327 Demeclocycline in the treatment of the syndrome of inappropriate secretion of antidiuretic hormone W H PERKS, E H WALTERS,' I P TAMS, AND K PROWSE From the Department of Respiratory Physiology, City General Hospital, Stoke-on-Trent, Staffordshire, UK ABSTRACT Fourteen patients with the syndrome of inappropriate secretion of antidiuretic hormone (SIADH) have been treated with demethylchlortetracycline (demeclocycline) 1200 mg daily. In 12 patients the underlying lesion was malignant. The serum sodium returned to normal (> 135 mmol/l) in all patients after a mean of 8-6 days (SD+5-3 days). Blood urea rose significantly from the pretreatment level of 4-2±2-3 mmol/l to 10-1±5-1 mmol/l at ten days (p<0 001). The average maximum blood urea was 13-4-6-8 mmol/l. In four patients the urea rose above 20 mmol/l, and in two of these demecyocycline was discontinued because of this rise. The azotaemia could be attributed to a combination of increased urea production and a mild specific drug-induced nephrotoxicity. Discontinuation of demeclocycline in six patients led to a fall in serum sodium, in one case precipitously, and return of the urea towards normal levels. Demeclocycline appears therefore to be an effective maintenance treatment of SIADH, and the azotaemia that occurs is reversible and probably dose dependent. The syndrome of inappropriate secretion of anti- Methods http://thorax.bmj.com/ diuretic hormone (SIADH) has become increas- ingly recognised as a treatable cause of stupor and Fourteen patients with a diagnosis of SIADH confusion in patients with a wide variety of based on the criteria of De Troyer and Demanet diseases (De Troyer and Demanet, 1976).
    [Show full text]
  • RECEPTOR ANTAGONISTS Vasopressin V2 Receptor Antagonists
    1 RECEPTOR ANTAGONISTS Vasopressin V2 receptor antagonists J G Verbalis 232 Building D, Division of Endocrinology and Metabolism, Georgetown University School of Medicine, 4000 Reservoir Road NW, Washington DC 20007, USA (Requests for offprints should be addressed toJGVerbalis; Email: [email protected]) Abstract Hyponatremia, whether due to the syndrome of inappropriate antidiuretic hormone secretion (SIADH) or disorders of water retention such as congestive heart failure and cirrhosis, is a very common problem encountered in the care of medical patients. To date, available treatment modalities for disorders of excess arginine vasopressin (AVP) secretion or action have been limited and suboptimal. The recent discovery and development of nonpeptide AVP V2 receptor antagonists represents a promising new treatment option to directly antagonize the effects of elevated plasma AVP concentrations at the level of the renal collecting ducts. By decreasing the water permeability of renal collecting tubules, excretion of retained water is promoted, thereby normalizing or improving hypo-osmolar hyponatremia. In this review, SIADH and other water retaining disorders are briefly discussed, after which the published preclinical and clinical studies of several nonpeptide AVP V2 receptor antagonists are summarized. The likely therapeutic indications and potential complications of these compounds are also described. Journal of Molecular Endocrinology (2002) 29, 1–9 Introduction heart failure (CHF) and cirrhosis with ascites. In these disorders, a relatively decreased intravascular Arginine vasopressin (AVP), the ‘antidiuretic volume and/or pressure leads to water retention as a hormone,’ is the major physiological regulator of result of both decreased distal delivery of glomerular renal free water excretion. Increased AVP secretion filtrate and secondarily elevated plasma AVP levels.
    [Show full text]
  • Prospects for New Antibiotics: a Molecule-Centered Perspective
    The Journal of Antibiotics (2014) 67, 7–22 & 2014 Japan Antibiotics Research Association All rights reserved 0021-8820/14 www.nature.com/ja REVIEW ARTICLE Prospects for new antibiotics: a molecule-centered perspective Christopher T Walsh and Timothy A Wencewicz There is a continuous need for iterative cycles of antibiotic discovery and development to deal with the selection of resistant pathogens that emerge as therapeutic application of an antibiotic becomes widespread. A short golden age of antibiotic discovery from nature followed by a subsequent golden half century of medicinal chemistry optimization of existing molecular scaffolds emphasizes the need for new antibiotic molecular frameworks. We bring a molecule-centered perspective to the questions of where will new scaffolds come from, when will chemogenetic approaches yield useful new antibiotics and what existing bacterial targets merit contemporary re-examination. The Journal of Antibiotics (2014) 67, 7–22; doi:10.1038/ja.2013.49; published online 12 June 2013 Keywords: antibiotics; mechanism of action; natural products; resistance A PERSONAL PATHWAY TO ANTIBIOTICS RESEARCH chemical logic and molecular machinery and, in part, with the hope For one of us (CTW), a career-long interest in antibiotics1 was that one might learn to reprogram natural antibiotic assembly lines to spurred by discussions on the mechanism of action of engineer improved molecular variants. D-fluoroalanine2,3 during a seminar visit, as a second year assistant We have subsequently deciphered many of the rules
    [Show full text]
  • Strategies in Stewardship and Why Some Antimicrobials Should Be Protected
    Strategies in Stewardship and Why Some Antimicrobials Should Be Protected Matt Crotty, PharmD Clinical Pharmacist – Infectious Diseases Methodist Dallas Medical Center September 7, 2017 Disclosures • Acted as a consultant – Nabriva Therapeutics AG – Theravance Biopharma Objectives • Define antimicrobial stewardship • Discuss current and future strategies for antimicrobial stewardship to promote judicious use of antimicrobials • Describe the reasons for “protecting” antimicrobials Outline • The Problem • Antimicrobial stewardship – Concept – Strategies • Passive • Active • Other (…prevention would be nice) • Reasons antimicrobials are protected • Collaboration Misuse adversely impacts patients – Resistance “…. the microbes are educated to resist penicillin and a host of penicillin-fast organisms is bred out… In such cases the thoughtless person playing with penicillin is morally responsible for the death of the man who finally succumbs to infection with the penicillin-resistant organism. I hope this evil can be averted.” - Sir Alexander Fleming, June 1945 Nature Reviews: Drug Discovery. 2007: 6; 8-12. Antibiotics are misused in hospitals . An estimated 30-50% of antimicrobial use in hospitals is inappropriate . Misused in a variety of ways • Given when not needed • Continued when no longer necessary • Wrong dose/drug for infection • Broad spectrum for susceptible organisms IDSA Statement on ‘Antibiotic Resistance: Promoting Critically Needed Antibiotic Research and Development and Appropriate Use (“Stewardship”) of these Precious Drugs’ -Before the House Committee on Energy and Commerce Subcommittee on Health; June 9, 2010 Antibiotics are misused in hospitals CDC, MMWR. 2014; 63. Misuse adversely impacts patients – Adverse Effects . Perception that there is (almost) no risk and (almost) all benefit to giving an antibiotic . Antibiotics account for nearly 1 in 5 (19.3%) of drug-related adverse events • >140,000 ED visits/year • Admission required for 6.1% of adverse events .
    [Show full text]
  • Outpatient Parenteral Antimicrobial Therapy for Infectious Diseases 3Ed
    Outpatient Parenteral Antimicrobial Therapy Handbook of For Infectious Diseases 3ed The Sponsored by Medicines Company ©2016 CRG Publishing, a Division of The Curry Rockefeller Group, LLC, and the Infectious Diseases Society of America All rights reserved. No part of the OPAT eHandbook may be reproduced in any form by any means (eg, electronically, mechanically, copied, recorded, or otherwise), or utilized by any information storage or retrieval system, without the written permission of CRG Publishing and the Infectious Diseases Society of America. For information, contact Rights and Permissions Coordinator, The Curry Rockefeller Group, Suite 410, 660 White Plains Road, Tarrytown, New York, 10591, USA. The Sponsored by Medicines Company Supported by Handbook of Outpatient Parenteral Antimicrobial Therapy For Infectious Diseases 3ed Akshay B. Shah, MD, MBA, FIDSA Anne H. Norris, MD Chair, OPAT Workgroup of IDSA Co-Chair, OPAT Guidelines Committee of IDSA Metro Infectious Disease Consultants Associate Professor of Medicine Editors Clinical Assistant Professor Perelman School of Medicine, University of Pennsylvania Wayne State University Philadelphia, PA Detroit, MI CRG PUBLISHING, A DIVISION OF THE CURRY ROCKEFELLER GROUP, LLC Geneve M. Allison, MD, MSc, FACP Ajay Mathur, MD, FACP Akshay B. Shah, MD, MBA, FIDSA Assistant Professor Regional VP Chair, OPAT Workgroup of IDSA Tufts University School of Medicine ID Care Metro Infectious Disease Consultants Clinical Assistant Professor Antonio C. Arrieta, MD David S. McKinsey, MD Wayne State University Division Chief, Infectious Diseases Physician Children’s Hospital of Orange County Infectious Disease Associates of Kansas City Nabin Shrestha, MD, MPH, FACP, FIDSA Infectious Disease Physician Kavita P. Bhavan, MD Sandra B.
    [Show full text]
  • Prospects for New Antibiotics: a Molecule-Centered Perspective
    The Journal of Antibiotics (2014) 67, 7–22 & 2014 Japan Antibiotics Research Association All rights reserved 0021-8820/14 www.nature.com/ja REVIEW ARTICLE Prospects for new antibiotics: a molecule-centered perspective Christopher T Walsh and Timothy A Wencewicz There is a continuous need for iterative cycles of antibiotic discovery and development to deal with the selection of resistant pathogens that emerge as therapeutic application of an antibiotic becomes widespread. A short golden age of antibiotic discovery from nature followed by a subsequent golden half century of medicinal chemistry optimization of existing molecular scaffolds emphasizes the need for new antibiotic molecular frameworks. We bring a molecule-centered perspective to the questions of where will new scaffolds come from, when will chemogenetic approaches yield useful new antibiotics and what existing bacterial targets merit contemporary re-examination. The Journal of Antibiotics (2014) 67, 7–22; doi:10.1038/ja.2013.49; published online 12 June 2013 Keywords: antibiotics; mechanism of action; natural products; resistance A PERSONAL PATHWAY TO ANTIBIOTICS RESEARCH chemical logic and molecular machinery and, in part, with the hope For one of us (CTW), a career-long interest in antibiotics1 was that one might learn to reprogram natural antibiotic assembly lines to spurred by discussions on the mechanism of action of engineer improved molecular variants. D-fluoroalanine2,3 during a seminar visit, as a second year assistant We have subsequently deciphered many of the rules
    [Show full text]